Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy

Molecular Therapy — Oncolytics(2022)10.1016/j.omto.2022.10.011Source: DataRank Database

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy is a research paper published in Molecular Therapy — Oncolytics (2022). On theSindex it has a DataRank of 0. It has been cited 49 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access49 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.72)OA: goldTopics (19)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Sandro Matosevic ORCID,Xinyu Wu ORCID

Live enrichment

PubMed:36420307 PMC:PMC9676278 OpenAlex:https://openalex.org/W4308485502

National Institutes of Health

Grant: R21CA256413

V Foundation for Cancer Research

Grant: D2019-039

National Institutes of Health

Grant: 1R21CA256413-01

Usurping TIGIT and CD73 activities with responsive, genetically-engineered NK cells as immunotherapy for glioblastoma

FWCI

2.72

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

goldLicense: CC BY NC ND

journalhttps://doi.org/10.1016/j.omto.2022.10.011

publisherhttps://doi.org/10.1016/j.omto.2022.10.011

publisherhttps://api.elsevier.com/content/article/PII:S2372770522001334?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2372770522001334?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36420307

Fields of Study

Immune Cell Function and InteractionCAR-T cell therapy researchRNA Interference and Gene Delivery03 medical and health sciences0302 clinical medicine

Keywords

ImmunotherapyGeneGene engineeringBiologyImmunologyGeneticsImmune systemRecombinant DNANK cellsTumor MicroenvironmentCar-nkNeoplasms. Tumors. Oncology. Including cancer and carcinogensReviewRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being